CentralCharts: Supercharge your portfolio with groundbreaking tools.

...

bitcoin #crypto #cryptocurrencies Consider dropping a like if you enjoyed the video! Check out our sponsor, Cheqd: ......

- Geoffrey Morphy terminated as CEO and Nicolas Bonta appointed on interim basis - - CEO Executive search nearing completion - This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated March 8, 2024, to its short form base shelf prospectus dated November 10, 2023. TORONTO, Ontario and BROSSARD, Québec, May 13, 2024 (GLOBE NEWSWIRE) -- Bitfarms Ltd. (NASDAQ/TSX: BITF), a global vertically integrated Bitcoin mining company, today...

Lilium is keen to leverage France’s unique aerospace heritage and vast supplier base in aerospace and electrification to expand its high-volume production capacity of the Lilium Jet Discussion of industrial footprint expansion into France, potential government subsidies and loan guarantees expected to be concluded in the coming weeks Lilium expansion could create up to 850 new direct jobs in France Lilium Jet production expected to boost French export volumes as vast majority of produced Jets...

- First Quarter 2024 Total Revenue More Than Doubled Year-over-Year to $21.5 Million - - Driven by 59% Year-over-Year Growth in Direct-to-Consumer Division - ORLANDO, Fla., May 13, 2024 (GLOBE NEWSWIRE) -- Abacus Life, Inc. (“Abacus” or the “Company”) (NASDAQ: ABL), a pioneering alternative asset manager specializing in longevity and actuarial technology, today reported results for the first quarter ended March 31, 2024. “We are pleased with our continued momentum, delivering yet...

― Entered into a collaboration and ex-U.S. license agreement with Sanofi for the development and commercialization of losmapimod ― ― On track to report topline data for Phase 3 REACH trial of losmapimod in facioscapulohumeral muscular dystrophy (FSHD) in the fourth quarter of 2024 ― ― Industry veteran, Patrick Horn M.D., Ph.D., appointed as chief medical officer ― ― Conference call and webcast scheduled for 8:00 a.m. ET today ― CAMBRIDGE, Mass., May 13, 2024 (GLOBE NEWSWIRE) --...

First patient dosed in Phase 1 clinical trial for the treatment of solid tumors; initial data anticipated in 2024 All treatment-arm patients in the Phase 1 heme program remain relapse-free with no detectable disease, with a median follow-up of >10 months Closed upsized underwritten public offering with gross proceeds of $167.8 million, extending runway into the fourth quarter of 2026 WALTHAM, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage...

JERUSALEM, May 13, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and small therapeutic proteins, today announced that it has been selected to present data for its investigational program EB612 at the Endocrine Society ENDO 2024 Annual Meeting which will be held on June 1-4, 2024 in Boston, Massachusetts. The EB612 program is being developed by Entera to provide the first oral PTH(1-34) tablet...